The Horizon Europe programme has funded the ITHEMYC project to establish a critical path for selection of promising innovative adjunct TB immunotherapies and progress 2 of these immunotherapies to completion of preclinical proof of concept.
The Horizon Europe programme has funded the ITHEMYC project to establish a critical path for selection of promising innovative adjunct TB immunotherapies and progress 2 of these immunotherapies to completion of preclinical proof of concept.
info@tbvi.eu
+31 (0) 6 1099 5196
Runderweg 6
8219 PK Lelystad